Vanda Pharmaceuticals is showcasing VQW-765 at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
VQW-765 for social anxiety is a compelling Phase 3 story — there's been no novel pharmacotherapy for social anxiety in decades, and an on-demand dosing model would be transformative. At APA, psychiatrists who manage anxiety disorders daily will be interested. Results expected end of 2026.
Ask about: Phase 3 trial design; on-demand vs. daily dosing data; how they envision the prescribing model; competitive landscape (currently just SSRIs/SNRIs/benzos); Phase 2 efficacy signal details. Novel MOA + novel indication + on-demand model = high interest from anxiety-focused psychiatrists.
Social anxiety's core symptoms are inherently behavioral — VoiceVitals captures anxiety markers (vocal tremor, speech hesitation, linguistic hedging) in naturalistic video assessments. ePRO+ enables on-demand assessment aligned with on-demand dosing. This is one of the most natural Videra fits at the entire conference — the assessment model mirrors the treatment model.
Set up a follow-up with Vanda Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →